Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Study Identifier
M05-750
CT.gov Identifier
NCT00300469
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dyslipidemia
  • Cardiovascular Disease
    • Study Drug
  • ABT-335
  • Atorvastatin
  • Placebo
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subjects with mixed dyslipidemia - Subjects must agree to utilize adequate birth control methods and to adhere to the American Heart Association (AHA) diet
    Exclusion Criteria:
    - Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial. - Patients who are taking certain medications or unstable dose of specific medications. - Women who are pregnant or plan on becoming pregnant, or women who are lactating.

    Protocol Summary

    The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335)

    + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with

    multiple abnormal lipid levels in the blood.

    Study Locations

    Location
    Status
    Location
    Global Medical Information
    North Chicago, Illinois, United States, 60064
    Status
    Not applicable